Plain-English translation of NCT04902703 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called —a drug that boosts the immune system—might help slow down or even improve thinking and memory problems in people with mild-to-moderate Alzheimer's disease. You would receive this medication through daily injections under the skin for six months (24 weeks) and be compared to people receiving a placebo (a dummy injection with no active medicine). The researchers want to know if this treatment is safe and whether it can make a real difference in how well your brain works.
Alzheimer's disease slowly damages memory and thinking skills, and current treatments have limited ability to slow it down. This medication works by activating the immune system in new ways, and early research suggests it might help protect the brain—so researchers want to test whether this treatment can actually help people with Alzheimer's.
You likely qualify if…
You likely don't qualify if…
You would come to the study site regularly over six months to receive either the medication or a placebo injection under your skin, given seven days a week. Throughout this time, you would have visits to check how you are doing, including memory and thinking tests, brain imaging, and blood or spinal fluid samples to look at biomarkers of Alzheimer's disease. Your caregiver would also be involved in reporting on any changes in your daily activities and well-being.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States